Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children

Annals of Tropical Paediatrics

Volumn 25, Issue 1, 2005, Pages 17-22

  Vinh, Ha ^a   Duong, Nguyen Minh ^a   Phuong, Le Thi ^c   Truong, Nguyen Thanh ^a   Van Be Bay, Phan ^c   Wain, John ^b,d   Diep, To Song ^a   Ho, Vo Anh ^c   White, Nicholas J ^b,d   Day, Nicholas P J ^b,d   Parry, Christopher M ^b,d,e  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c Dong Thap Provincial Hospital   (Viet Nam)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; NALIDIXIC ACID; OFLOXACIN;

CHILD DEVELOPMENT; CHILD HEALTH; DISEASE PREVALENCE; DRUG PRESCRIBING; TYPHOID;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; CHILD; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SALMONELLA TYPHI; SHORT COURSE THERAPY; TREATMENT FAILURE; TYPHOID FEVER; VIET NAM;

ASIA; EASTERN HEMISPHERE; EURASIA; SOUTHEAST ASIA; VIET NAM; WORLD;

SALMONELLA TYPHI;

EID: 20144366435     PISSN: 02724936     EISSN: None     Source Type: Journal    
DOI: 10.1179/146532805X23308     Document Type: Article

References (23)

1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347:1770-82.
2. Hoa NTT, Diep TS, Wain J, et al. Community-acquired septicaemia in southern Vietnam: the importance of multi-drug resistant Salmonella typhi. Trans R Soc Trop Med Hyg 1998; 92:503-8.
3. Bhutta ZA, Khan IA, Molla AM. Therapy of multidrug-resistant typhoid fever with oral cefixime versus intravenous ceftriaxone. Pediatr Infect Dis J 1994; 13:990-4.
4. Girgis NI, Sultan Y, Hammad O, Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multi-drug-resistant Salmonella typhi septicemia in children. Pediatr Infect Dis J 1995; 14:603-5.
5. Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. J Infect Dis 2000; 31:1134-8.
6. Phuong CXT, Kneen R, Anh NT, et al. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatr Infect Dis J 1999; 18:245-8.
7. Dutta P, Rasaily R, Saha MR, et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993; 37:1197-9.
8. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animal versus children. Clin Infect Dis 1997; 25 1196-204.
9. Hien TT, Bethell DB, Nguyen TT, et al. Short courses of ofloxacin for treatment of multi-drug-resistant typhoid. Clin Infect Dis 1995; 20:917-23.
10. Vinh H, Wain J, Vo TN, et al. 2 or 3 days of ofloxacin treatment for uncomplicated multi-drug-resistant typhoid fever in children. Antimicrob Agents Chemother 1996; 40:958-61.
11. Chinh NT, Solomon T, Mai XT, et al. Short courses of ofloxacin for the treatment of enteric fever. Trans R Soc Trop Med Hyg 1997; 91: 347-9.
12. Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25 1404-10.
13. Brown JC, Shanahan PM, Jesudason MV, Thomson CJ, Aymes SG. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996; 37:891-900.
14. Threlfall EJ, Skinner JA, Ward LR. Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A. J Antimicrob Chemother 2001; 48 740-1.
15. Chinh NT, Parry CM, Ly NT, et al. A randomised controlled comparison of azithromycin and ofloxacin for multi-drug-resistant and nalidixic acid resistant enteric fever. Antimicrob Agents Chemother 2000; 44:1855-9.
16. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Re-evaluating fluoroquinolone breakpoints for Salmonella enterica serotype typhi and for non-typhi Salmonellae. Clin Infect Dis 2003; 37 75-81.
17. Aarestrup FM, Wiuff C, Mølbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003; 47:827-9.
18. Parry CM. The treatment of multi-drug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004; 98: 413-22.
19. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 7th edn. Approved Standard. NCCLS document M7-A4 Villanova, PA: NCCLS, 1997.
20. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial sensitivity testing; NCCLS Eighth informational supplement. M100-S8, vol 18. Villanova, PA: NCCLS, 1998.
21. Duong NM, Vinh Chau NV, Van Anh DC, et al. Short course fleroxacin in the treatment of typhoid fever. JAMA Southeast Asia 1995; 11 (suppl):21-5.
22. Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones. Arch Dis Child 1996; 74:44-6.
23. Doherty CP, Saha SK, Cutting WA. Typhoid fever, ciprofloxacin and growth in young children. Ann Trop Paediatr 2000; 20 297-303.